Immatics (NASDAQ:IMTX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immatics (NASDAQ:IMTX) from a sell rating to a hold rating in a research report released on Saturday.

IMTX has been the topic of several other research reports. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Immatics in a research note on Thursday, December 4th. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of Immatics in a report on Monday, November 24th. Guggenheim boosted their target price on shares of Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immatics currently has an average rating of “Moderate Buy” and an average price target of $18.80.

Immatics Stock Down 0.5%

NASDAQ IMTX opened at $10.45 on Friday. Immatics has a twelve month low of $3.30 and a twelve month high of $12.41. The stock has a market cap of $1.27 billion, a P/E ratio of -10.24 and a beta of 1.36. The company’s 50-day simple moving average is $10.14 and its 200 day simple moving average is $7.99.

Immatics (NASDAQ:IMTX) last released its quarterly earnings data on Monday, November 17th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. Immatics had a negative return on equity of 24.16% and a negative net margin of 146.13%.The company had revenue of $6.10 million for the quarter, compared to the consensus estimate of $12.53 million. Research analysts anticipate that Immatics will post -0.72 earnings per share for the current year.

Institutional Investors Weigh In On Immatics

A number of hedge funds have recently added to or reduced their stakes in IMTX. Bank of America Corp DE increased its position in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Immatics during the second quarter valued at approximately $59,000. Insigneo Advisory Services LLC acquired a new stake in shares of Immatics in the third quarter valued at approximately $103,000. Engineers Gate Manager LP bought a new position in Immatics in the 2nd quarter worth approximately $124,000. Finally, Fox Run Management L.L.C. bought a new position in Immatics in the 2nd quarter worth approximately $136,000. Institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.